Catalent, Inc. CTLT
Set alert
63.48 0.00 0.00%
At close · Dec 17
63.44 Day range 63.50
52-week range unavailable
- Open
- 63.49
- Prev close
- 63.48
- Mkt cap
- 11.52B
- Vol
- 13.67M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 63.44
- High
- 63.50
- Earnings
- Nov 5, 2024
2Y chart
Events in this range
- Aug 29, 2023Earnings: —; estimate 0.1; surprise —%
- May 8, 2024Earnings: —; estimate 0.24; surprise —%
- Aug 29, 2024Earnings: —; estimate 0.46; surprise —%
- Nov 5, 2024Earnings: —; estimate 0.11; surprise —%
Signals (87)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Dec 11, 2024 | 1 year ago |
| RSI: Overbought | Dec 9, 2024 | 1 year ago |
| RSI: Overbought | Dec 5, 2024 | 1 year ago |
| SMA: Bullish | Nov 22, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 20, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 19, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 7, 2024 | 1 year ago |
| RSI: Oversold | Oct 29, 2024 | 2 years ago |
| SMA: Bearish | Oct 22, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 2, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 6, 2024 | 2 years ago |
| RSI: Overbought | Sep 4, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 30, 2024 | 2 years ago |
| RSI: Overbought | Aug 29, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 9, 2024 | 2 years ago |
| RSI: Overbought | Aug 8, 2024 | 2 years ago |
| RSI: Overbought | Aug 6, 2024 | 2 years ago |
| RSI: Overbought | Jul 25, 2024 | 2 years ago |
| RSI: Overbought | Jul 23, 2024 | 2 years ago |
| RSI: Overbought | Jul 11, 2024 | 2 years ago |
| SMA: Bullish | Jun 21, 2024 | 2 years ago |
| SMA: Bearish | Jun 14, 2024 | 2 years ago |
| SMA: Bullish | Jun 6, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 5, 2024 | 2 years ago |
| RSI: Oversold | May 28, 2024 | 2 years ago |
| MACD: Sell Signal | May 10, 2024 | 2 years ago |
| SMA: Bearish | May 8, 2024 | 2 years ago |
| SMA: Bullish | May 7, 2024 | 2 years ago |
| MACD: Buy Signal | May 2, 2024 | 2 years ago |
| SMA: Bearish | Apr 12, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 12, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 9, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 14, 2024 | 2 years ago |
| RSI: Overbought | Feb 2, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 26, 2024 | 2 years ago |
| RSI: Overbought | Jan 26, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 23, 2024 | 2 years ago |
| RSI: Overbought | Jan 9, 2024 | 2 years ago |
| SMA: Bullish | Jan 5, 2024 | 2 years ago |
| SMA: Bearish | Jan 3, 2024 | 2 years ago |
| SMA: Bullish | Jan 2, 2024 | 2 years ago |
| SMA: Bearish | Dec 29, 2023 | 2 years ago |
| SMA: Bullish | Dec 27, 2023 | 2 years ago |
| SMA: Bullish | Dec 13, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 13, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 8, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 14, 2023 | 2 years ago |
| RSI: Oversold | Nov 9, 2023 | 2 years ago |
| RSI: Oversold | Nov 6, 2023 | 2 years ago |
| RSI: Oversold | Oct 31, 2023 | 3 years ago |
| RSI: Oversold | Oct 25, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 20, 2023 | 3 years ago |
| SMA: Bearish | Oct 17, 2023 | 3 years ago |
| SMA: Bullish | Oct 13, 2023 | 3 years ago |
| SMA: Bearish | Oct 12, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 12, 2023 | 3 years ago |
| SMA: Bullish | Oct 11, 2023 | 3 years ago |
| SMA: Bearish | Sep 21, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 18, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 29, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bearish | Aug 22, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Aug 17, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 1, 2023 | 3 years ago |
| RSI: Overbought | Jul 26, 2023 | 3 years ago |
| SMA: Bullish | Jun 29, 2023 | 3 years ago |
| SMA: Bearish | Jun 28, 2023 | 3 years ago |
| SMA: Bullish | Jun 15, 2023 | 3 years ago |
| MACD: Buy Signal | May 19, 2023 | 3 years ago |
| MACD: Sell Signal | May 8, 2023 | 3 years ago |
| RSI: Oversold | May 8, 2023 | 3 years ago |
| MACD: Buy Signal | May 1, 2023 | 3 years ago |
| RSI: Oversold | Apr 14, 2023 | 3 years ago |
| SMA: Bearish | Apr 11, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| SMA: Bearish | Apr 3, 2023 | 3 years ago |
| SMA: Bullish | Mar 31, 2023 | 3 years ago |
| SMA: Bearish | Mar 30, 2023 | 3 years ago |
| SMA: Bullish | Mar 24, 2023 | 3 years ago |
| SMA: Bearish | Mar 23, 2023 | 3 years ago |
| RSI: Overbought | Mar 3, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 22, 2023 | 3 years ago |
| RSI: Overbought | Feb 1, 2023 | 3 years ago |
| RSI: Overbought | Jan 27, 2023 | 3 years ago |
| RSI: Overbought | Jan 20, 2023 | 3 years ago |
Next earnings
Nov 5, 2024
Expected Nov 5, 2024. Consensus EPS estimate 0.11.
Financials — quick view
CTLT Revenue — quarterly 1.02B
CTLT Net income — quarterly -129.00M
CTLT EPS — quarterly -0.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | 0.11 | — | — | — |
| Aug 29, 2024 | Jun 1, 2024 | 0.46 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.24 | — | — | — |
| Aug 29, 2023 | Jun 1, 2023 | 0.10 | — | — | — |
News
- Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
- Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services
- Cartherics and Catalent Expand Commercial License Agreement
- Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
- SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
- Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
- Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Your note
Sign in to keep a note on CTLT — it syncs with the Stock Master app.